CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy-dependent ferroptosis.
Ziqi ShangZhengdong LuoYifeng WangQi LiuYiwei XinMengjiao ZhangXinyang LiShunjie ZengLongchen YuXin ZhangYi ZhangPublished in: Journal of cellular physiology (2023)
Cisplatin is the first-line chemotherapy for gastric cancer (GC). However, its efficacy is dampened by the development of chemoresistance, which leads to poor prognosis in GC patients. Recently, evidence has revealed that circular RNAs (circRNAs) and dysregulation of autophagy-dependent ferroptosis play critical roles in cancer chemoresistance. Herein, for the first time we report that circHIPK3 has a vital role in GC cisplatin resistance. CircHIPK3 regulated cisplatin resistance by targeting autophagy and ferroptosis. In brief, knockdown circHIPK3 decreased GC cell cisplatin resistance by enhancing ferroptosis via the miR-508-3p/Bcl-2/beclin1/SLC7A11 axis. Taken together, our results demonstrate that ferroptosis is a promising strategy to ameliorate cisplatin resistance. Importantly, serum exosomal circHIPK3 could also be a noninvasive indicator to evaluate cisplatin resistance in GC.
Keyphrases
- cell death
- poor prognosis
- oxidative stress
- signaling pathway
- end stage renal disease
- long non coding rna
- gas chromatography
- chronic kidney disease
- ejection fraction
- transcription factor
- cell therapy
- peritoneal dialysis
- young adults
- patient reported outcomes
- rectal cancer
- bone marrow
- papillary thyroid
- simultaneous determination